# Respiratory Sector

Canonical URL: https://biopharmsignal.com/sector/respiratory

Respiratory includes companies developing therapies, devices, and diagnostics for lung disease, airway inflammation, pulmonary hypertension, COPD, asthma, and related disorders. It captures both chronic-care franchises and more specialized pulmonary development programs.

Companies currently grouped under Respiratory: 11

## Recent Sector News

- 2026-09-08 12:17 EST — VERU — [Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial](https://biopharmsignal.com/news/VERU/veru-advances-oral-sabizabulin-following-positive-preclinical-data-showing-poten-7873a352) — Source: Veru Inc
- 2026-09-04 11:00 EST — INSM — [Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eefcc024) — Source: Insmed
- 2026-09-03 11:00 EST — INSM — [Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026](https://biopharmsignal.com/news/INSM/insmed-to-present-data-across-its-respiratory-portfolio-including-new-late-break-06f589e4) — Source: Insmed
- 2026-09-02 12:30 EST — VERU — [Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference](https://biopharmsignal.com/news/VERU/veru-to-participate-in-fireside-chat-at-the-2026-cantor-global-healthcare-confer-d6f725fc) — Source: Veru Inc
- 2026-09-02 12:00 EST — XAIR — [Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference](https://biopharmsignal.com/news/XAIR/beyond-air-to-participate-in-the-2026-cantor-global-healthcare-conference-6e406389) — Source: Beyond Air
- 2026-09-01 20:05 EST — LUNG — [Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/LUNG/pulmonx-corporation-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-b2c3056f) — Source: Pulmonx
- 2026-08-31 12:00 EST — XAIR — [Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)](https://biopharmsignal.com/news/XAIR/beyond-air-receives-fda-breakthrough-device-designation-for-lungfit-go-to-treat--aedb37d4) — Source: Beyond Air
- 2026-08-27 20:05 EST — LUNG — [Pulmonx to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/LUNG/pulmonx-to-participate-in-upcoming-investor-conferences-c73972ec) — Source: Pulmonx
- 2026-08-26 11:00 EST — INSM — [Insmed to Present at September 2026 Investor Conferences](https://biopharmsignal.com/news/INSM/insmed-to-present-at-september-2026-investor-conferences-e8eaed49) — Source: Insmed
- 2026-08-25 11:00 EST — XAIR — [Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments](https://biopharmsignal.com/news/XAIR/beyond-air-enters-definitive-agreement-to-sell-its-neuronos-stake-to-univo-pharm-44cfb6b7) — Source: Beyond Air
- 2026-08-24 11:00 EST — INSM — [BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease](https://biopharmsignal.com/news/INSM/brinsupri-brensocatib-approved-by-japan-s-ministry-of-health-labour-and-welfare--cea66b26) — Source: Insmed
- 2026-08-13 12:15 EST — PULM — [Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger](https://biopharmsignal.com/news/PULM/pulmatrix-announces-second-quarter-2026-financial-results-and-progress-on-merger-b9f3cb56) — Source: Pulmatrix
- 2026-08-13 11:00 EST — XAIR — [Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update](https://biopharmsignal.com/news/XAIR/beyond-air-reports-financial-results-for-the-quarter-ended-june-30-2026-and-prov-419dcf14) — Source: Beyond Air
- 2026-08-12 20:29 EST — RVPH — [Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/RVPH/reviva-reports-second-quarter-2026-financial-results-and-recent-business-highlig-2c8ebd7b) — Source: Reviva Pharmaceuticals
- 2026-08-10 12:30 EST — TBPH — [Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TBPH/theravance-biopharma-inc-reports-second-quarter-2026-financial-results-and-provi-d61c1ffa) — Source: Theravance Biopharma
- 2026-08-10 10:30 EST — VERU — [Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress](https://biopharmsignal.com/news/VERU/veru-reports-fiscal-2026-third-quarter-financial-results-and-phase-2b-plateau-cl-5d15fd94) — Source: Veru Inc
- 2026-08-06 11:00 EST — INSM — [Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/INSM/insmed-reports-second-quarter-2026-financial-results-and-provides-business-updat-e68db27f) — Source: Insmed
- 2026-08-04 12:30 EST — VERU — [Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss](https://biopharmsignal.com/news/VERU/veru-announces-notice-of-allowance-for-key-methods-of-use-u-s-patent-for-enobosa-a0328556) — Source: Veru Inc
- 2026-08-04 12:00 EST — XAIR — [Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026](https://biopharmsignal.com/news/XAIR/beyond-air-schedules-conference-call-to-discuss-financial-results-for-the-quarte-a4714eb0) — Source: Beyond Air
- 2026-08-03 12:30 EST — VERU — [Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th](https://biopharmsignal.com/news/VERU/veru-to-report-fiscal-2026-third-quarter-financial-results-on-august-10th-3c5f1e88) — Source: Veru Inc

## Companies

- [BLPH](https://biopharmsignal.com/company/BLPH) — Bellerophon Therapeutics
- [XAIR](https://biopharmsignal.com/company/XAIR) — Beyond Air
- [INSM](https://biopharmsignal.com/company/INSM) — Insmed
- [PIRS](https://biopharmsignal.com/company/PIRS) — Pieris
- [PULM](https://biopharmsignal.com/company/PULM) — Pulmatrix
- [LUNG](https://biopharmsignal.com/company/LUNG) — Pulmonx
- [RVPH](https://biopharmsignal.com/company/RVPH) — Reviva Pharmaceuticals
- [SVRA](https://biopharmsignal.com/company/SVRA) — Savara, Inc.
- [TBPH](https://biopharmsignal.com/company/TBPH) — Theravance Biopharma
- [VRNA](https://biopharmsignal.com/company/VRNA) — Verona Pharma
- [VERU](https://biopharmsignal.com/company/VERU) — Veru Inc